careful reading of the publication that arose from our roundtable conference. His comments about the magnitude of a difference between active treatments using the NICE guidelines are reasonable up until he critiques the meta-analysis of mirtazapine and SSRIs. 1 Here, he focuses on the slight remission rate difference in favor of mirtazapine (NNT = 23) and claims that we were misleading readers by failing to interpret "minor differences as anything more than clinically